Vincent T. DeVita Jr., an oncologist who had been director ofthe National Cancer Institute from 1980-88, has been elected tothe board of ImClone Systems Inc. New York-based ImClone(NASDAQ:IMCL) is developing therapeutics to treat selectedcancers, disorders of the blood and immune system, andinflammatory diseases.

Medizone International Inc. of New York has named PeterMelera and Wayne Chou to its board. Melera is the director ofthe graduate program in molecular and cell biology at theUniversity of Maryland and Chou is the co-owner of a softwaresecurity company. Medizone is developing an ozone-basedtreatment for diseases caused by lipid enveloped viruses.

California Biotechnology Inc. of Mountain View, Calif., hasnamed to its new scientific advisory board: Dr. Edgar Haber,Elkan R. Blout professor of health science at the Harvard Schoolof Public Health; Russell Ross, Ph.D., chairman and professor ofthe Department of Pathology at the University of WashingtonSchool of Medicine; and Dr. Bengt Samuelsson, president andprofessor of physiological chemistry at the Karolinska Institutetof Stockholm, Sweden. California Biotechnology (NASDAQ:CBIO)is developing therapeutics, emphasizing cardiopulmonaryconditions, wound-healing, diabetes and obesity.

Cephalon Inc. of West Chester, Pa., has appointed Philip S.Portoghese to its science advisory board. Portoghese is aprofessor of medicinal chemistry and pharmacology at theUniversity of Minnesota in Minneapolis. Cephalon(NASDAQ:CEPH) is developing treatments for stroke andneurodegenerative disorders.

(c) 1997 American Health Consultants. All rights reserved.